How emerging investment models are rewiring biotech funding structures for efforts in rare disease.
Casey McPherson
Advertisement
Casey McPherson, founder and CEO, AlphaRose Therapeutics.
Articles by Casey McPherson
Advertisement
Latest Updated Articles
The New Capital of Care in Rare DiseaseJune 10th 2026
Advertisement
Advertisement
Trending on PharmExec
1
New U.S. Guidance Lays Out Exemptions for 100% Tariffs: Report
2
Pharming CEO Fabrice Chouraqui Steps Down Amid Strategic Disagreement with Board
3
Roundup: Hengrui Pharma and Novo Enter Exclusive License Agreement for HRS-1596, AstraZeneca Enters Collaboartion with Summit Therapeutics
4
As Peptide Rulemaking Stalls, FDA Enforcement Moves Forward
5